Discontinuation of disease-modifying therapies in elderly people with multiple sclerosis


  • This study found that the discontinuation of disease-modifying therapies (DMTs) appears safe for individuals with multiple sclerosis (MS) who are over 50 and are experiencing benign/burn-out MS.  

Why this matters

    DMTs provide short term-benefit in people with active MS; however, evidence supporting the continued use of DMTs in people with inactive MS is sparse.